O'Day Daniel Patrick 4

What Happened

• Daniel P. O'Day, Chairman & CEO of Gilead Sciences, had 38,396 performance-share award shares vest (acquisition reported as an award) on Feb 27, 2026 and sold a total of 9,999 shares in open-market transactions that same day for aggregate proceeds of approximately $1,447,858. Reported sale lots: 3,481 shares @ $144.04 ($501,386), 6,419 shares @ $145.18 ($931,901), and 100 shares @ $145.71 ($14,571). The award acquisition is compensation-related; the sales were executed under a pre-established trading plan.

Key Details

• Transaction date: 2026-02-27; Form 4 filed 2026-03-02 (timely — within SEC two-business-day window).
• Award (A): 38,396 shares granted/vested (per footnote, part of March 10, 2025 performance-share award; performance condition certified).
• Sales (S): 9,999 shares sold in three lots for total cash proceeds ≈ $1.45M. Reported per-lot prices shown above; filing footnotes note sale price ranges of $143.63–$145.65 and that detailed per-price breakdowns are available on request.
• Plan/authorization: Sales reported as executed pursuant to a Rule 10b5-1 trading plan adopted Feb 28, 2025 (footnote F2).
• Shares owned after transaction: Not specified in the excerpt of the filing provided.

Context

• The 38,396 shares reported as an acquisition were performance-based awards that vested upon certification — this is compensation income, not an open-market purchase. The nearly 10,000 shares sold were executed under a 10b5-1 plan, which is a prearranged program often used to avoid trading-window timing issues. The filing is factual and timely; it does not indicate the insider’s motivations.